BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 964 filers reported holding BAXTER INTL INC in Q3 2014. The put-call ratio across all filers is 1.07 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $1,686 | +21.9% | 39,442 | +10.3% | 0.18% | +23.3% |
Q4 2023 | $1,383 | -100.0% | 35,771 | -21.6% | 0.15% | -55.9% |
Q2 2022 | $2,929,000 | +88.4% | 45,599 | +127.4% | 0.33% | +80.9% |
Q1 2022 | $1,555,000 | +251.0% | 20,049 | +288.5% | 0.18% | +273.5% |
Q4 2021 | $443,000 | -83.9% | 5,160 | -84.9% | 0.05% | -82.3% |
Q2 2021 | $2,753,000 | +398.7% | 34,198 | +396.7% | 0.28% | +211.2% |
Q4 2020 | $552,000 | +19.7% | 6,885 | +20.1% | 0.09% | +20.3% |
Q3 2020 | $461,000 | -36.2% | 5,735 | -31.7% | 0.07% | -32.1% |
Q2 2020 | $723,000 | -42.1% | 8,400 | -48.2% | 0.11% | -37.0% |
Q3 2018 | $1,249,000 | +106.4% | 16,203 | +74.0% | 0.17% | +92.2% |
Q1 2018 | $605,000 | +22.5% | 9,314 | +22.0% | 0.09% | +2.3% |
Q4 2017 | $494,000 | +42.8% | 7,633 | +37.9% | 0.09% | +57.1% |
Q3 2017 | $346,000 | +24.5% | 5,535 | +20.9% | 0.06% | +7.7% |
Q2 2017 | $278,000 | -31.2% | 4,580 | -49.7% | 0.05% | -51.9% |
Q4 2016 | $404,000 | -25.2% | 9,102 | -30.8% | 0.11% | -26.0% |
Q1 2016 | $540,000 | +158.4% | 13,145 | +104.8% | 0.15% | +105.6% |
Q3 2015 | $209,000 | -16.4% | 6,418 | +86.0% | 0.07% | -78.0% |
Q2 2014 | $250,000 | -35.6% | 3,451 | -41.5% | 0.32% | -51.4% |
Q3 2013 | $388,000 | – | 5,900 | – | 0.66% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 36,000,000 | $2,658,240,000 | 18.52% |
SECTOR GAMMA AS | 721,058 | $53,243,000 | 8.85% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,747,061 | $202,843,000 | 5.38% |
Veritas Asset Management LLP | 8,852,005 | $653,632,000 | 5.36% |
Knowledge Leaders Capital, LLC | 79,384 | $5,862,000 | 4.39% |
HealthCor Management, L.P. | 1,800,000 | $132,912,000 | 4.22% |
Progressive Investment Management Corp | 79,282 | $5,854,000 | 3.78% |
13D Management LLC | 200,318 | $14,791,000 | 3.77% |
ARGENT CAPITAL MANAGEMENT LLC | 1,288,236 | $95,123,000 | 3.42% |
Chiron Investment Management, LLC | 612,787 | $45,248,000 | 3.12% |